A phase Ib trial of oral CBLC 137 in patients with advanced solid tumours that are resistant or refractory to standard care

Trial Profile

A phase Ib trial of oral CBLC 137 in patients with advanced solid tumours that are resistant or refractory to standard care

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs CBLC 137 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Apr 2015 No dose-limiting toxicities have been observed to date, according to a Cleveland BioLabs media release.
    • 06 Jan 2015 Interim results published in Cleveland BioLabs media release.
    • 06 Jan 2015 Dosing of the ninth cohort is underway, according to a Cleveland BioLabs media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top